Busulfan

  • TRADE NAMES: Citosulfan; Leukosulfan; Mablin; Misulban; Myleran (GSK)
  • INDICATIONS: Chronic myelogenous leukemia, bone marrow disorders
  • CLASS: Alkylating agent
  • HALF-LIFE: 3.4 hours (after first dose)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Acetaminophen, Aldesleukin, Itraconazole, Metronidazole, Voriconazole

PREGNANCY CATEGORY: D

BLACK BOX WARNING
LEUKEMOGENESIS and PANCYTOPENIA

See full prescribing information for complete boxed warning.

Our database has 47 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 06/03/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top